Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kodiak Sciences (KOD) Cash & Equivalents (2016 - 2026)

Kodiak Sciences filings provide 11 years of Cash & Equivalents readings, the most recent being $169.5 million for Q1 2026.

  • Quarterly Cash & Equivalents rose 22.09% to $169.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $169.5 million through Mar 2026, up 22.09% year-over-year, with the annual reading at $209.9 million for FY2025, 24.86% up from the prior year.
  • Cash & Equivalents hit $169.5 million in Q1 2026 for Kodiak Sciences, down from $209.9 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $671.7 million in Q1 2022 and bottomed at $72.0 million in Q3 2025.
  • Average Cash & Equivalents over 5 years is $239.5 million, with a median of $197.9 million recorded in 2024.
  • The largest annual shift saw Cash & Equivalents crashed 80.4% in 2022 before it skyrocketed 119.27% in 2023.
  • Kodiak Sciences' Cash & Equivalents stood at $196.8 million in 2022, then skyrocketed by 45.11% to $285.5 million in 2023, then crashed by 41.13% to $168.1 million in 2024, then grew by 24.86% to $209.9 million in 2025, then dropped by 19.22% to $169.5 million in 2026.
  • Per Business Quant, the three most recent readings for KOD's Cash & Equivalents are $169.5 million (Q1 2026), $209.9 million (Q4 2025), and $72.0 million (Q3 2025).